Oxford Biomedica plc, a gene and cell therapy group, has agreed to an extension and update to its commercial supply Agreement with Novartis for the manufacture of lentiviral vectors for several Novartis CAR-T products.   Oxford Biomedica initially licensed its LentiVector platform to Novartis in the field of CAR-T in October 2014, followed by a 5-year commercial supply agreement signed by Oxford Biomedica and Novartis in December 2019.   Under the terms of the updated agreement, the parties ...